Skip to main content
Top
Published in: BMC Neurology 1/2024

Open Access 01-12-2024 | Overactive Bladder | Research

Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson’s disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson’s disease

Authors: Hong Jin, Yiheng Du, Jiahui Yan, Jinru Zhang, Xiaoyu Cheng, Chengjie Mao, Jing Chen, Chun-feng Liu

Published in: BMC Neurology | Issue 1/2024

Login to get access

Abstract

Objectives

Overactive bladder (OAB) and dyskinesia are frequent complications in patients with Parkinson’s disease (PD). However, the correlation between OAB and dyskinesia has been insufficiently explored. The purpose of this study was to examine the relationship between dyskinesia, OAB, and clinical characteristics among individuals with PD.

Methods

1338 PD patients were included in the present study. Demographic features were compared between patients with or without dyskinesia and OAB symptoms. Logistic regression was conducted on dyskinesia to screen clinically relevant factors. Overactive Bladder Symptom Score (OABSS) was further used to stratify the association between the severity of OAB and the occurrence of dyskinesia.

Results

This study indicates that both dyskinesia and OAB are significantly related to disease severity and cognitive status. PD patients with dyskinesia and OAB having higher UPDRS scores (p < 0.001), H-Y scores (p < 0.001), NMSQ (p < 0.001) and MoCA scores (p < 0.001), and lower MMSE scores (p < 0.001) are identified. The multivariate logistic regression confirms that disease duration (p = 0.041), LEDD (p < 0.001), UPDRSII (p < 0.001), MoCA (p = 0.024), urgency (p < 0.001), frequency (p < 0.001), and nocturia (p = 0.002) are independent risk factors for dyskinesia. Trend analysis indicates that the risk of dyskinesia significantly increases when patients exhibit moderate to severe OAB symptoms (OABSS > 5) (p < 0.001). No significant interactions were found between OABSS and age, gender, disease duration, LEDD, and NMSQ scores in different subgroups, indicating that dyskinesia is more pronounced in patients with OABSS > 5.

Discussion

This study provides compelling evidence supporting the strong correlation between OAB and dyskinesia in PD patients, emphasizing the presence of shared pathogenic mechanisms between these two conditions. Our findings underscore the importance of considering both OAB and dyskinesia in the clinical management of PD, investigating the intricate connections between OAB and dyskinesia could unveil valuable insights into the complex pathophysiology of PD and potentially identify novel therapeutic targets for more effective PD treatment strategies.
Literature
2.
go back to reference Xu H, Cheng X, Song Q, Yang Y, Wang C, Kang X. Induced dopaminergic neurons for Parkinson’s disease therapy: targeting the striatum or midbrain/substantia Nigra pars compacta? Neurosci Bull. 2022;38:820–4.CrossRefPubMedPubMedCentral Xu H, Cheng X, Song Q, Yang Y, Wang C, Kang X. Induced dopaminergic neurons for Parkinson’s disease therapy: targeting the striatum or midbrain/substantia Nigra pars compacta? Neurosci Bull. 2022;38:820–4.CrossRefPubMedPubMedCentral
3.
go back to reference Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):11–6.CrossRef Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20(Suppl 11):11–6.CrossRef
4.
go back to reference Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(Pt 11):2297–305.CrossRefPubMed Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(Pt 11):2297–305.CrossRefPubMed
5.
go back to reference Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58.CrossRefPubMed Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58.CrossRefPubMed
6.
7.
go back to reference Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015;132:96–168.CrossRefPubMed Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson’s disease. Prog Neurobiol. 2015;132:96–168.CrossRefPubMed
8.
go back to reference Group PDMC, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.CrossRef Group PDMC, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.CrossRef
9.
go back to reference Kasten M, Hartmann C, Hampf J, et al. Genotype-phenotype relations for the Parkinson’s disease genes parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord. 2018;33:730–41.CrossRefPubMed Kasten M, Hartmann C, Hampf J, et al. Genotype-phenotype relations for the Parkinson’s disease genes parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord. 2018;33:730–41.CrossRefPubMed
10.
11.
go back to reference Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson’s disease. Mov Disord. 2010;25:2–12.CrossRefPubMed Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Genitourinary dysfunction in Parkinson’s disease. Mov Disord. 2010;25:2–12.CrossRefPubMed
12.
go back to reference Benli E, Ozer FF, Kaya Y, Ozcan TS, Ayyildiz A. Is there a difference between Parkinson disease patients and a control group in terms of urinary symptoms and quality of life? Turk J Med Sci. 2016;46:1665–71.CrossRefPubMed Benli E, Ozer FF, Kaya Y, Ozcan TS, Ayyildiz A. Is there a difference between Parkinson disease patients and a control group in terms of urinary symptoms and quality of life? Turk J Med Sci. 2016;46:1665–71.CrossRefPubMed
13.
go back to reference Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737–45.CrossRefPubMed Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21:737–45.CrossRefPubMed
14.
go back to reference McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson’s disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8–16.CrossRefPubMed McDonald C, Winge K, Burn DJ. Lower urinary tract symptoms in Parkinson’s disease: prevalence, aetiology and management. Parkinsonism Relat Disord. 2017;35:8–16.CrossRefPubMed
15.
go back to reference Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson’s disease patients and normal controls. Parkinsonism Relat Disord. 2003;10:67–71.CrossRefPubMed Hobson P, Islam W, Roberts S, Adhiyman V, Meara J. The risk of bladder and autonomic dysfunction in a community cohort of Parkinson’s disease patients and normal controls. Parkinsonism Relat Disord. 2003;10:67–71.CrossRefPubMed
16.
go back to reference Benson GS, Raezer DM, Anderson JR, Saunders CD, Corriere JN Jr. Effect of levodopa on urinary bladder. Urology. 1976;7:24–8.CrossRefPubMed Benson GS, Raezer DM, Anderson JR, Saunders CD, Corriere JN Jr. Effect of levodopa on urinary bladder. Urology. 1976;7:24–8.CrossRefPubMed
17.
go back to reference Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.CrossRefPubMed Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.CrossRefPubMed
18.
go back to reference Pavy-Le Traon A, Cotterill N, Amarenco G, et al. Clinical rating scales for urinary symptoms in Parkinson disease: critique and recommendations. Mov Disord Clin Pract. 2018;5:479–91.CrossRefPubMedPubMedCentral Pavy-Le Traon A, Cotterill N, Amarenco G, et al. Clinical rating scales for urinary symptoms in Parkinson disease: critique and recommendations. Mov Disord Clin Pract. 2018;5:479–91.CrossRefPubMedPubMedCentral
19.
go back to reference Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17:867–76.CrossRefPubMed Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord. 2002;17:867–76.CrossRefPubMed
20.
go back to reference Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord. 2012;27:1125–8.CrossRefPubMed Lessig S, Nie D, Xu R, Corey-Bloom J. Changes on brief cognitive instruments over time in Parkinson’s disease. Mov Disord. 2012;27:1125–8.CrossRefPubMed
21.
go back to reference Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21:916–23.CrossRefPubMed Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21:916–23.CrossRefPubMed
22.
23.
go back to reference Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137:2731–42.CrossRefPubMedPubMedCentral Cilia R, Akpalu A, Sarfo FS, et al. The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137:2731–42.CrossRefPubMedPubMedCentral
24.
go back to reference Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–71.CrossRefPubMed Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–71.CrossRefPubMed
25.
go back to reference Reichmann H, Lees A, Rocha JF, Magalhaes D, Soares-da-Silva P, investigators O. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:1-9. Reichmann H, Lees A, Rocha JF, Magalhaes D, Soares-da-Silva P, investigators O. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study. Transl Neurodegener. 2020;9:1-9.
26.
go back to reference Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson’s disease: the contribution of epidemiological studies. Sleep Med Rev. 2011;15:41–50.CrossRefPubMed Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, Logroscino G. Sleep disorders and the natural history of Parkinson’s disease: the contribution of epidemiological studies. Sleep Med Rev. 2011;15:41–50.CrossRefPubMed
27.
go back to reference Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756–60.CrossRefPubMed Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol. 2006;63:1756–60.CrossRefPubMed
28.
go back to reference Luca A, Monastero R, Baschi R, et al. Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort. Sci Rep. 2021;11:867.CrossRefPubMedPubMedCentral Luca A, Monastero R, Baschi R, et al. Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort. Sci Rep. 2021;11:867.CrossRefPubMedPubMedCentral
29.
go back to reference Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22:220–5.CrossRefPubMed Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22:220–5.CrossRefPubMed
30.
go back to reference Murchison AG, Fletcher C, Cheeran B. Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson’s disease on DBS (GPi). Parkinsonism Relat Disord. 2016;27:107–8.CrossRefPubMed Murchison AG, Fletcher C, Cheeran B. Recurrence of dyskinesia as a side-effect of mirabegron in a patient with Parkinson’s disease on DBS (GPi). Parkinsonism Relat Disord. 2016;27:107–8.CrossRefPubMed
32.
go back to reference Bourdenx M, Nilsson A, Wadensten H, et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson’s disease and l-DOPA-induced dyskinesia. Neurobiol Dis. 2014;62:307–12.CrossRefPubMed Bourdenx M, Nilsson A, Wadensten H, et al. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson’s disease and l-DOPA-induced dyskinesia. Neurobiol Dis. 2014;62:307–12.CrossRefPubMed
34.
go back to reference Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993;12:203–9.CrossRefPubMed Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn. 1993;12:203–9.CrossRefPubMed
35.
go back to reference Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18:573–8.CrossRefPubMed Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord. 2003;18:573–8.CrossRefPubMed
36.
go back to reference Uchiyama T, Sakakibara R, Yamamoto T, et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson’s disease. Mov Disord. 2009;24:2386–90.CrossRefPubMed Uchiyama T, Sakakibara R, Yamamoto T, et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson’s disease. Mov Disord. 2009;24:2386–90.CrossRefPubMed
Metadata
Title
Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson’s disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson’s disease
Authors
Hong Jin
Yiheng Du
Jiahui Yan
Jinru Zhang
Xiaoyu Cheng
Chengjie Mao
Jing Chen
Chun-feng Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-024-03578-3

Other articles of this Issue 1/2024

BMC Neurology 1/2024 Go to the issue